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Abstract 
Background: The ability of Zn(II) and Cu(II) metal complexes of non‑steroidal anti‑inflammatory drugs (NSAIDs) to 
inhibit acute arterial inflammation in vivo has been studied.
Results: When acute vascular inflammation was induced in normocholesterolemic New Zealand White rabbits by 
inserting a non‑occlusive silastic collar around the common carotid artery, a single oral dose of Cu(II)‑indomethacin 
(Cu(II)Indo, 3 mg/kg) administered by laparotomy achieved a 67 % (8.2 ± 1.7 vs. 2.7 ± 0.4 image units, p < 0.05) reduc‑
tion in endothelial expression of vascular cell adhesion molecule‑1 (VCAM‑1) but did not inhibit endothelial intercel‑
lular adhesion molecule (ICAM‑1) expression significantly. Treatment with Cu(II)‑acemetacin (Cu(II)ACM, 3 mg/kg) led 
to a profound 88 % (8.2 ± 1.7 vs. 1.0 ± 0.5 image units, p < 0.01) reduction in endothelial VCAM‑1 expression but did 
not inhibit ICAM‑1 expression, while treatment with Zn(II)‑acemetacin (Zn(II)ACM, 3 mg/kg) led to an 84 % (19.3 ± 1.0 
vs. 3.1 ± 1.2 image units, p < 0.01) reduction in endothelial ICAM‑1 expression and did not inhibit VCAM‑1 expression. 
No adverse gastric, hepatic or renal effects were observed in treated animals.
Conclusion: These findings provide the “proof of concept” that this novel class of drug, where there is complexation 
of NSAIDs with metal ions, has substantial anti‑inflammatory effects in an animal model of acute vascular inflamma‑
tion with the possibility of low rates of adverse effects.
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Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
amongst the most commonly prescribed drugs in the 
community, specifically for the treatment of a wide vari-
ety of inflammatory conditions [1]. However, patients 
receiving non-selective NSAIDs often experience abdom-
inal discomfort, while some develop serious gastro-intes-
tinal (GI) complications such as ulceration, bleeding, 
perforation or obstruction [2].
It was, therefore postulated that with the advent of 
selective cyclooxygenase-2 (COX-2) inhibitors, the num-
ber of NSAID-related gastric complications would be 
reduced [3]. However, current evidence demonstrates that 
selective COX2 inhibitors (‘coxibs’) have important cardi-
ovascular side-effects that include increased risk for myo-
cardial infarction, stroke, heart failure and hypertension 
[4]. Due to concerns regarding CV risks, the American 
Heart Association recommends that treatment with cox-
ibs should be limited to patients in whom no appropriate 
alternatives can be found, and then only in the lowest dose 
for the shortest duration necessary [5]. A subsequent joint 
study with the American College of Cardiology Foun-
dation and the American College of Gastroenterology 
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recommended concomitant therapy with proton pump 
inhibitors such as esomeprazole, to offset the GI dam-
age from NSAID use [6]. According to the Pharmaceuti-
cal Benefits Scheme, esomeprazole use represents the 
fourth highest cost to Australia in terms of national health 
expenditure.
An alternative approach, used in veterinary prac-
tice [7], is the complexation of NSAIDs with metal 
ions, which results in enhanced gastric protection [7] 
compared with the parent NSAID. Another potential 
strategy for developing NSAIDs with attenuated GI 
side effects is to use acemetacin (ACMH), a glycolic 
ester of indomethacin (IndoH) with inherent anti-
inflammatory activity and better gastric tolerability 
compared with IndoH [8]. In addition, ACMH has a 
reportedly safer pharmacokinetic profile in the elderly 
[8]. Therefore, it is an ideal candidate for complexation 
with biologically relevant metals such as copper (Cu) 
and zinc (Zn) [9].
Given the pressing need for alternative safer NSAID-
type drugs that could be applied to a large range of medi-
cal indications, we have investigated the impact of IndoH 
and copper bound Indo (Cu(II)Indo) with that of copper 
bound (Cu(II)ACM), and zinc bound ACM (Zn(II)ACM) 
on acute arterial inflammation in  vivo in the New Zea-
land White (NZW) rabbit.
Results and discussion
The mean plasma concentrations of total choles-
terol, HDL cholesterol and apoA-I in the rabbits were 
0.84  ±  0.1, 0.66  ±  0.05  mM/l, and 0.76  ±  0.07  mg/
ml, respectively. At the time of sacrifice, there was 
no measurable effect on the concentration of any of 
these parameters with any of the treatments that were 
administered.
Effect of treatment on endothelial VCAM‑1 expression 
(Fig. 1a–g)
There was marked up regulation in endothelial expres-
sion of VCAM-1 24  h post-carotid collar insertion 
(Fig.  1a, b, p  <  0.01). Treatment with IndoH (3  mg/kg) 
led to a 75 % decrease in endothelial VCAM-1 expression 
(8.2 ± 1.7 vs. 2.1 ± 1.4 image units) (p < 0.05) (Fig. 1c). 
Treatment with Cu(II)Indo (3  mg/kg) led to a 67  % 
(8.2 ± 1.7 vs. 2.7 ± 0.4 image units) (p < 0.05) reduction 
in endothelial VCAM-1 expression (Fig.  1d). Treatment 
with Cu(II)ACM (3 mg/kg) resulted in an 88 % (8.2 ± 1.7 
vs. 1.0 ± 0.5 image units) (p < 0.01) reduction of endothe-
lial VCAM-1 expression (Fig. 1e). The 39 % (8.2 ± 1.7 vs. 
5.0 ±  1.4 image units, p =  0.19) reduction in VCAM-1 
expression, which resulted from treatment with Zn(II)
ACM (3  mg/kg), did not achieve statistical significance 
(Fig. 1f ).
Effect of treatment on endothelial ICAM‑1 expression 
(Fig. 2a–g)
Insertion of a carotid collar markedly up-regulated 
endothelial ICAM-1 expression (Fig.  2a, b, p  <  0.01). 
Treatment with IndoH (3 mg/kg) led to a 79 % decrease in 
endothelial ICAM-1 expression [19.3 ± 1.0 vs. 4.1 ± 1.4 
image units (p < 0.01) Fig. 2c]. Treatment with Cu(II)Indo 
(3 mg/kg) led to a 28 % (19.3 ± 1.0 vs. 13.9 ± 6.3 image 
units, p = 0.43) decrease in ICAM-1 expression (Fig. 2d). 
There was a 43 % (19.3 ± 1.0 vs. 11.0 ± 3.6 image units, 
p  =  0.07) decrease in ICAM-1 expression with Cu(II)
ACM (3  mg/kg), which was not statistically significant 
(Fig.  2e), whereas treatment with Zn(II)ACM (3  mg/
kg) led to a 84 % (19.3 ±  1.0 vs. 3.1 ±  1.2 image units) 
(p < 0.01) decrease in ICAM-1 expression (Fig. 2f ).
Toxicity data
The active ingredients were well tolerated by all animals. 
Both macroscopic and microscopic immunohistochemi-
cal analyses revealed no evidence of gastric, hepatic or 
renal toxicity. Examination of the entire length of the 
stomach, small and large bowel showed no evidence of 
ulceration, gastrointestinal bleeding or inflammation. 
On histology there was no evidence of acute hepatitis or 
nephritis in any of the animals.
In this work, we have demonstrated for the first time 
that Cu and Zn bound anti-inflammatory agents can 
also be effective treatments for acute vascular inflam-
mation in vivo. The degree of anti-inflammatory activity 
observed was found to be similar to that achieved with 
IndoH at equivalent to the FDA recommended maxi-
mum therapeutic dose (RMTD). Furthermore, this new 
class of anti-inflammatory agents showed no signs of 
organ (stomach, small and large intestine, liver, and kid-
ney) acute toxicity at this dose.
Specifically, we observed that Cu(II)-bound Indo 
and ACM achieved a comparable level of inhibition of 
endothelial VCAM-1 expression as observed after treat-
ment with IndoH. Interestingly, Zn(II)-bound ACM 
was able to decrease expression of endothelial ICAM-1 
substantially, despite a lack of significant inhibition 
of VCAM-1 expression, which indicated that Zn(II)
ACM inhibits inflammation independent of the canoni-
cal nuclear factor-κB (NF-κB) pathway. Importantly, the 
results of this study are comparable to a similar study 
in which the anti-inflammatory effects of the athero-
protective agent lipid-free apolipoprotein A-I (apoA-I) 
were investigated [10]. However the degree of inhibition 
of VCAM and ICAM achieved warrants larger studies 
including mechanistic studies at the MRNA level to fur-
ther delineate these effects in vivo.
Treatments with both NSAIDs and coxibs are asso-
ciated with significant rates of GI and cardiovascular 
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(CV) pathology [2–4]. It was initially postulated that 
selective coxibs may specifically decrease GI adverse 
side effects. However, it is now apparent that, despite 
a reduction in GI complications with selective coxibs, 
serious CV events may occur [11]. Therefore, there is 
pressing clinical need for the development of effective 
anti-inflammatory agents with a wider safety and thera-
peutic window.
Fig. 1 Effect of treatment on endothelial expression of VCAM‑1. Normocholesterolemic NZW rabbits were treated with either saline, IndoH (3 mg/
kg), Cu(II)Indo (3 mg/kg), Cu(II)ACM (3 mg/kg) or Zn(II)ACM (3 mg/kg) (n = 4 per group) at the time of peri‑arterial collar insertion. The animals were 
sacrificed 24 h after collar insertion. Representative sections of carotid arteries stained for VCAM‑1 expression (×40 magnification) are shown. a a 
representative control, non‑collared artery from a saline‑treated animal, b a collared artery section from a saline‑treated animal, c a section of a col‑
lared artery where the animal is treated with IndoH, d a section of a collared artery from an animal treated with Cu(II)Indo, e a collared artery section 
from an animal treated with Cu(II)ACM and f a section of a collared artery from an animal is treated with Zn(II)ACM. In g the results are expressed 
graphically as mean ± SEM (*p < 0.05; **p < 0.01)
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An early strategy to circumvent the inherent toxicity of 
NSAID use was by means of NSAID complexation with 
metals, particularly Cu. This arose from the research of 
Hangarter in the mid-twentieth century [12], and the 
hypothesis of Sorenson in the 1990s that the in  vivo 
activity of NSAIDs might be due to binding with endoge-
nous Cu [13], and the gastric-sparing effect of the Cu(II)-
NSAID complexes. Many other Cu(II)-NSAID complexes 
Fig. 2 Effect of treatment on endothelial expression of ICAM‑1. A non‑occlusive collar was inserted around the left common carotid artery of 
normolipidemic NZW rabbits, as described in the legend to Fig. 1. Representative sections of carotid arteries stained for ICAM‑1 expression (×40 
magnification) are shown in the panels. a a representative section from a control, non‑collared artery from a saline‑treated animal, b a collared 
artery section from a saline‑treated animal, c a section of a collared artery from an animal treated with indomethacin (IndoH), d a section of a col‑
lared artery from a Cu(II)‑Indo‑treated animal, e a section of a collared artery from an animal treated with Cu(II)‑ACM and f a section of a collared 
artery from an animal treated with Zn(II)‑ACM. In g the results are expressed graphically as mean ± SEM (**p < 0.01)
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have since been synthesised [7, 13] as well as those of 
other metals, such as Zn(II) [14], for the assessments of 
their anti-inflammatory, anti-cancer and anti-diabetic 
effects.
Acemetacin (systematic name: 2-[2-(1-(4-chlorobenzoyl)- 
5-methoxy-2-methyl-1H-indol-3-yl)acetoxy]acetic acid) is 
an IndoH prodrug with inherent anti-inflammatory activ-
ity. ACMH has been on the market for over 35 years and 
although its GI-protective advantage relative to IndoH 
is well-established [8], relatively little is known about 
its mode of action [15]. ACMH is known to be rapidly 
absorbed and converted to IndoH in vivo, with complete 
biotransformation within 1 h of ingestion. It has been sug-
gested that the reduced GI toxicity of ACMH results from 
its lack of stimulation of leucocyte-endothelial adherence 
within mesenteric venules, a crucial event in the genesis of 
NSAID gastropathy [15], hence it is considered a suitable 
candidate for evaluation of its anti-inflammatory activity 
and non-ulcerogenic potential in a variety of conditions 
and diseases. Further, expansion of the current protocol 
to include ACMH and/or other market available NSAIDs 
would also be of value.
Preliminary investigations of the Cu(II) complex of 
ACM provide useful pointers to the relative safety and 
efficacy and dose–response of the complex compared 
with the parent NSAID. A comparable level of inhibi-
tion of cell adhesion molecule expression by IndoH and 
the metal complexes of Indo and ACM is indicative of the 
anti-inflammatory potency of all of these classes of drugs. 
Both VCAM-1 and ICAM-1 are important early markers 
of atherogenesis, and serum levels of soluble VCAM-1 
and soluble ICAM-1 independently predict CV events 
[16]. It is likely that the anti-inflammatory effects of these 
compounds are, at least in part, explained by inhibition 
of NF-κB, where variable magnitudes of inhibition of 
VCAM-1 and ICAM-1 can be attributed to the differing 
effects on the regulators of their expression, especially in 
relation to the ACM compounds.
For clinical applications, it is necessary to consider 
the safety of profiles of these drugs, which are associ-
ated with their mode(s) of action. Cu(II)Indo exhibits an 
enzymatic anti-oxidant-like superoxide dismutase (SOD) 
activity, with an IC50 value (0.04 µM) [17], which is com-
parable to other potent SOD-mimetic Cu complexes [18]. 
Indo complexes with either Cu(II) or Zn(II) showed an 
improvement in GI safety compared to the parent drug 
in rats and horses [17], but this was more evident for the 
Cu(II) complex and its SOD-like activity may contrib-
ute to the reduced GI toxicity. The clinically protective 
effects of the Cu complexes are further supported by the 
lack of GI, hepatic and renal toxicities observed in the 
NZW rabbit model used in the current study. Moreo-
ver, in Phase 1 human clinical trials for the treatment of 
proctitis, no toxicity was observed with Cu(II)Indo where 
normally the GI toxicity of NSAIDs would preclude treat-
ment for this condition [19].
A limitation of this study was the small numbers of ani-
mals per treatment group. This maybe of relevance to the 
differential inhibitory effects previously discussed. How-
ever, the degree of inhibition of VCAM-1 and ICAM-1 
achieved warrants larger studies to further delineate 
these effects in vivo; in particular investigation of effects 
on vascular inflammation of a combined therapy using 
both Cu(II)-NSAID and Zn(II)-NSAID compared with 
the parent NSAID alone. Also as the model used in our 
experiments was one of acute vascular inflammation, fur-
ther experiments investigating chronic vascular insults 
leading to atherosclerotic changes in the vessel wall are 
required. Finally, in regards to toxicity data, it is unlikely 
that major adverse effects would be observed after a sin-
gle dose of an NSAID in a small number of animals, as 
used in our study. In future studies we plan to expand 
the dose range and duration, as well as measure liver 
concentrations of copper and plasma concentrations of 
ceruloplasmin.
In conclusion, we have demonstrated for the first time 
that a single oral dose of Cu(II) and Zn(II)-bound Indo-
like compounds have marked anti-inflammatory effects 
in an acute model of vascular inflammation in vivo. This 
study establishes the “proof-of-concept” that such a class 
of drug can be effective with the additional benefit of 
no apparent GI, hepatic and renal toxicity. The ability of 
these compounds to inhibit the expression of adhesion 
molecules provides the initial evidence to further develop 
these drugs for human conditions of acute and chronic 
vascular inflammation and investigate their application in 
the treatment of other inflammation based disease states.
Methods
Synthesis and formulation of test compounds
Acemetacin, IndoH and zinc acetate dihydrate were 
obtained from Sigma Chemical Co. (St. Louis, MO, 
USA). Copper(II) acetate monohydrate (99.0  %) was 
obtained from Ajax Chemicals. All the chemicals were 
used without further purification for synthesis of the fol-
lowing active ingredients for testing: Cu(II)Indo, Cu(II)
ACM, (Fig. 3a) and Zn(II) ACM [9] (Fig. 3b). Tetraglycol 
and sorbitan monooleate (Span 80®) were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA). Fumed silica 
(Aerosil®) and medium chain triglyceride (MCT) oil were 
supplied by NatureVet Pty. Ltd. The MCT organogel was 
prepared by dissolving the active ingredient in tetraglycol 
(40 % w/w), Span 80 (20 % w/w) and MCT oil (adjusted to 
100 % w/w), and heating the mixture to 55–60 °C. Aerosil 
was added to the still warm solution, and mixed vigor-
ously to obtain a homogenous and transparent organogel. 
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The organogel was allowed to de-gas overnight prior to 
administration.
Ethics statement
Approval of the Sydney South West Area Health Service 
Animal Welfare Committee was obtained. Male New 
Zealand White (NZW) rabbits (from the IMVS, Ade-
laide, South Australia) weighing approximately 2.5  kg 
were maintained on a normal chow diet throughout the 
studies. A non-occlusive, silastic, peri-arterial collar was 
positioned around the left common carotid artery [10]. 
The collars were left in place for 24 h at which time the 
animals were sacrificed.
The formulation was administered via laparotomy 
under the same general anaesthesia immediately prior to 
collar insertion. The rabbits (n = 4 in each set of condi-
tions) received either saline (positive control), IndoH 
(3 mg/kg), Cu(II)Indo (3 mg/kg), Cu(II)ACM (3 mg/kg), 
or Zn(II)ACM (3 mg/kg). The non-collared right carotid 
artery was used as a control for each collared artery. The 
dosing for these experiments was determined on the 
basis of our previously published animal experiments, 
where there was minimal organ toxicity reported [9].
The collared segment of the left carotid artery and a 
30 mm segment of the contra-lateral carotid artery were 
collected. For immunohistochemical analysis, ring sec-
tions were cut from the arteries, fixed in cold ethanol and 
wax-embedded, as described previously [10].
A total of 8–10 contiguous sections (5 μm) and 20 ran-
dom fields/section were analysed for each vessel. Mouse 
anti-rabbit vascular cell adhesion molecule (VCAM)-1 
and intercellular adhesion molecule (ICAM)-1 antibodies 
(donated by Dr M. Cybulsky, University of Toronto) were 
used to assess endothelial expression of VCAM-1 and 
ICAM-1 as described previously [10].
Endothelial expression of VCAM-1 and ICAM-1 was 
determined by quantitative immunohistochemistry using 
ImagePro Plus 4.5 software (Media Cybernetics, Silver 
Spring, MD) [20]. The results, which represent the aver-
age positive staining above the threshold, set by a blinded 
experienced pathologist, for individual arterial sections 
are expressed as image units. Systematic sampling of each 
artery quadrant generated a single mean image unit value 
for staining for each artery. The mean of these values rep-
resents the amount of staining per treatment group, and 
was used for subsequent statistical comparison.
A Roche diagnostics kit (Basel, Switzerland) was used 
to determine plasma total cholesterol levels and HDL 
cholesterol levels as described [21]. The concentration of 
rabbit apoA-I was determined immunoturbidometrically 
[22]. These parameters were measured immediately prior 
to carotid surgery and at the time of sacrifice.
All results are expressed as mean  ±  SEM. Data 
obtained from digital analysis were regarded as continu-
ous variables and satisfied the Kolmogorov–Smirnov test 
to determine normal distribution. Statistical comparisons 
were then made by unpaired two-tailed Student’s t tests 
using Graph Pad Prism Version 4.0 (San Diego, CA). A 
value of p < 0.05 was considered statistically significant.
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